PURPOSE:Approximately 80 % of patients with prostate cancer will develop bone metastases, which often lead to bone pain and skeletal-related events.
Sr-89 is an established alternative for the palliation of bone pain in prostate cancer. We aimed to assess the effect of Sr-89 radionuclide therapy on quality of life (QOL) in prostate cancer patients with painful bone metastases.
MATERIALS AND METHODS: Thirteen patients received a single intravenous injection of Sr-89 at a dose of 2.0 MBq/kg. All patients underwent QOL evaluation prior to Sr-89 treatment and 1, 2, and 3 months afterward using the Japanese version of the EORTC QLQ-BM22, EORTC QLQ-C30, a VAS, and face scale. We also evaluated PSA and ALP response and toxicity of the Sr-89 therapy.
RESULTS: The pain characteristics subscale of the EORTC QLQ-BM22 was significantly reduced from 1 month onward compared with the baseline. The functional interference and psychosocial aspects subscales were significantly higher than baseline from 2 months onward. At 2 months, VAS indicated a significant reduction in pain as compared to the baseline. Sr-89 therapy caused a nonsignificant reduction in PSA and ALP levels. No patients had leukocyte toxicity, and one patient had grade 3 platelet toxicity.
CONCLUSION: Sr-89 radionuclide therapy can provide not only reduced pain characteristics but also better psychosocial aspects and functional interference in patients with painful bone metastases of prostate cancer.
Written by:
Kurosaka S, Satoh T, Chow E, Asano Y, Tabata KI, Kimura M, Tsumura H, Matsumoto K, Ishiyama H, Inoue Y, Hayakawa K, Baba S. Are you the author?
Department of Urology, Kitasato University School of Medicine, 1-15-1 Kitasato, Sagamihara, Kanagawa, 252-0374, Japan.
Reference: Ann Nucl Med. 2012 Apr 3. Epub ahead of print.
doi: 10.1007/s12149-012-0598-z
PubMed Abstract
PMID: 22477263
UroToday.com Prostate Cancer Section